Aclaris Therapeutics (NasdaqGS:ACRS) 2025 Conference November 12, 2025 01:20 PM ET Speaker2Awesome. Good afternoon, everyone. It's my pleasure to introduce the Aclaris Therapeutics team. Hugh Davis, Roland Kolbeck, and Will Roberts here joining us this afternoon. Maybe we could start off with just a brief overview of the company. Maybe, Hugh, do you want to start with that?Speaker1Sure. Yeah, hi. Thanks for having us. Aclaris is a clinical stage biotech. We have three assets in the clinic and another to com ...

Aclaris Therapeutics (NasdaqGS:ACRS) FY Conference November 12, 2025 11:00 AM ET Speaker2Ready to go?Yep.Excellent.Speaker1Okay, good morning, everybody, and thanks again for joining us. This is Guggenheim's Healthcare Innovations Conference. I'm really, I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggenheim. You know, really pleased to have with us Aclaris Therapeutics, and immediately to my right is Dr. Neal Walker, CEO and Chair of Aclaris. Also, joining us in the audience is Kevin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37581 Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or ...

公司季度业绩 - 季度每股亏损0.12美元，优于市场预期的亏损0.13美元，实现7.69%的盈利惊喜 [1] - 本季度每股亏损较去年同期的0.11美元有所扩大 [1] - 季度收入为330万美元，大幅超越市场预期107.75%，但低于去年同期的435万美元 [2] - 在过去四个季度中，公司有三次每股收益和三次收入表现超越市场预期 [2] 公司股价表现与展望 - 年初至今股价下跌约8.9%，同期标普500指数上涨15.6% [3] - 公司当前的Zacks评级为第3级（持有），预计近期表现将与市场同步 [6] - 未来业绩的关键将取决于管理层在财报电话会议中的评论以及盈利预期的修订趋势 [3][4] 未来业绩预期 - 对下一季度的普遍预期为每股亏损0.14美元，收入157万美元 [7] - 对本财年的普遍预期为每股亏损0.51美元，收入639万美元 [7] - 在本季度财报发布前，公司的盈利预期修订趋势好坏参半 [6] 行业表现与同业比较 - 公司所属的Zacks医疗-药物行业在250多个行业中排名前39% [8] - 同业公司Vivos Therapeutics预计在即将发布的报告中公布季度每股亏损0.50美元，较去年同期恶化25%，收入预计为400万美元，同比增长3.6% [9]

Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti- TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI- 052 - Pipeline: Oral Inhibitors: ITK Franchise ● Announced Anticipated Phase 2 Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3, in an Additional Indication: Aclaris expects to fur ...

- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Initiation of Phase 1b ...

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during t ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

公司活动 - 公司于2025年10月14日在纽约举办2025年研发日活动 [1] - 活动包含现场参与和网络直播两种形式 [1] 前瞻性陈述 - 本次演示包含根据1995年《私人证券诉讼改革法》定义的前瞻性陈述 [2] - 这些陈述代表公司截至2025年10月14日的判断 [2] - 前瞻性陈述可能涉及导致实际结果与预期产生重大差异的风险和不确定性 [2]

活动概述 - 公司于2025年10月14日在纽约举办2025年研发日活动 [1] - 活动包含现场参与和网络直播两种形式 [1] 陈述性质 - 本次演示包含基于1995年《私人证券诉讼改革法案》定义的前瞻性陈述 [2] - 陈述内容反映截至2025年10月14日的判断 [2]